Drug Trial News

RSS

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

15 Mar 2010

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.

15 Mar 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.

15 Mar 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals, Inc. announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

Data from ACCORD Lipid study: Abbott issues statement

Results were presented today on behalf of the National Heart, Lung and Blood Institute from ACCORD, a study in patients with diabetes that evaluated cardiovascular outcomes in three distinct studies – glycemic control, blood pressure control and lipid control.

15 Mar 2010

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Ipsen announced today the initiation of dosing in two phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.

15 Mar 2010

Regadenoson drug is safe for heart transplant patients: Study

The drug regadenoson is safe and poses fewer side effects than the conventional medication used during a cardiac nuclear stress test of heart transplant patients, according to a Henry Ford Hospital study.

15 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

15 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk

Australian drug development company CBio Limited today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S. The agreement relates to the development of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA).

12 Mar 2010

Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.

12 Mar 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat- (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).

12 Mar 2010

Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug

Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.

12 Mar 2010

Drug Trial News

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

CytRx plans five Phase 2 clinical trials with oncology drug candidates

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Data from ACCORD Lipid study: Abbott issues statement

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Regadenoson drug is safe for heart transplant patients: Study

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk

Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News